CommSec's Tom Piotrowski speaks with Bionomics Limited (BNO) CEO, Dr Deborah Rathjen about:

• BNO’s key programs including the group’s anxiety and Post Traumatic Stress Disorder treatment – BNC210, and cancer treatments BNC101 and BNC105 which have all continued to make recent progress.
• The progress of BNO’s agreement with Merck & Co. to develop novel drug candidates for its treatment for Alzheimer’s disease which delivered the first milestone payment of US $10 million earlier this year in February.
• BNO’s cash position which saw the group end 3Q17 with $50m, with net cash of $4.485 million generated for the 9 months to 31 March 2017